摘要
目的观察兰索拉唑与莫沙必利联合治疗反流性食管炎的临床效果。方法89例反流性食管炎患者随机分为两组，治疗组50例用兰索拉唑和莫沙必利，对照组39例用盐酸雷尼替丁胶囊，观察治疗前及治疗后4、8周的临床症状改善情况和内镜变化。结果用药4周时，治疗组反酸、恶心及胸骨后疼痛治疗有效率分别为78％、84％、82％，与对照组比较差异有统计学意义（P〈0．05）。用药8周结束时，治疗组反酸、悲心及胸骨后疼痛全部改善，总有效率分别是98％、98％和93％，明显优于对照组的64％、81％和73％（均P〈0．05）；内镜4周、8周复查治疗组与对照组食管黏膜病损愈合率分别为84％和62％，96％和77％，差异有统计学意义（P〈0．05）。结论兰索拉唑、莫沙必利联合用药是治疗反流性食管炎安全、有效的方法。
Objective To observe the clinical efficacy of combined therapy of lansoprazole and mosapride for treatment of reflux esophageal disease. Methods Eighty-nine patients with reflux esophageal disease were enrolled and divided into two groups randomly. Fifty patients in treatment group were administrated with lansoprazole and mosapride; 39 patients in control group were administrared with ranitidine. Symptoms and endoscope changes were observed before treatment and 4 weeks, 8 weeks after treatment. Results The symptoms（acid regurgitation, hear-burn,retrosternl pain） were relieved significantly 4 weeks after treatment compared with control group. All symptoms were improved better than the results at 4th week. The total response rates for the three symptoms above were 98 % ,98 % and 93 % respectively obviously better than 64 %, 81%, 73 % of control group （both P 〈 0.05 ）. Esophageal healing rates detected by endoscope were 84 % and 62 % after 4 weeks in treatment and control group respectively,and 96 % and 77 % after 8 weeks treatment（ P 〈 0.05）. Conclusion The combined therapy of lansoprazole and mosapride is safe and efficient for the treatment of reflux esophageal disease.
出处
《中国基层医药》
CAS
2008年第1期30-31,共2页
Chinese Journal of Primary Medicine and Pharmacy
